Drug Trial Radar · NCT05270837
Study to Evaluate the Safety and Efficacy of Pegvaliase in Adolescents (Ages 12-17) With Phenylketonuria
Last checked: Nov 20, 2026Latest source record: Jul 21, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
55
Actual
Start
Jun 17, 2022
Primary completion
Jan 14, 2025
Study completion Oct 2027
Sponsor
- Lead sponsor
- BioMarin PharmaceuticalBioMarin (BMRN)
- Sponsor type
- Industry
- First posted
- Mar 8, 2022
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 12 years, up to 17 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a Phase 3 open-label randomized controlled study enrolling approximately 54 adolescents with PKU. The study is designed to assess the safety and efficacy of pegvaliase injections.
Conditions
- Phenylketonuria (PKU)
Interventions
PegvaliaseDrug
Pegvaliase 2.5mg/10mg/20mg/40mg/60mg self-administered from 1 time up to 7 times a week
Diet OnlyOther
Diet Control
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change From Baseline in Blood Phe Concentration Following 72 Weeks (Average of the Week 69 and Week 73) on Study.Time frame: Baseline to Week 72 (average of the Week 69 and Week 73)
- Incidence of Treatment-emergent Adverse Events (Part 1)Time frame: Up to Week 73
- Percentage of Participants With Positive Anti-pegvaliase Total Antibody (TAb)Time frame: Baseline (Day 1), Week 73
- Percentage of Participants With Positive PAL IgG AntibodyTime frame: Baseline (Day 1), Week 73
- Percentage of Participants With Positive PAL IgM AntibodyTime frame: Baseline (Day 1), Week 73
- Percentage of Participants With Positive PEG IgG AntibodyTime frame: Baseline (Day 1), Week 73
- Percentage of Participants With Positive PEG IgM AntibodyTime frame: Baseline (Day 1), Week 73
- Percentage of Participants With Positive Neutralizing Antibodies (NAb)Time frame: Baseline (Day 1), Week 73
Locations
16 sites in 2 countries. Site status is shown where the registry gives one.
Phoenix Children's Hospital
Phoenix, Arizona
Arkansas Children's Hospital
Little Rock, Arkansas
Children's Hospital of Colorado
Aurora, Colorado
University of South Florida
Tampa, Florida
Ann and Robert H. Lurie Children's Hospital of Chicago
Chicago, Illinois
IU Health University Hospital
Indianapolis, Indiana
University of Kentucky College of Medicine
Lexington, Kentucky
Boston Children's Hospital
Boston, Massachusetts
University of Pittsburgh Medical Center
Pittsburgh, Pennsylvania
McGovern Medical School, University of Texas Health Science Center at Houston (UTHealth)
Houston, Texas
University of Utah Medical Center
Salt Lake City, Utah
University of Virginia School of Medicine
Charlottesville, Virginia
Children's Hospital of Wisconsin
Milwaukee, Wisconsin
Charité - Universitätsmedizin Berlin
Berlin, Germany
Universitätsklinikum Hamburg-Eppendorf
Hamburg, Germany
Universitat Mainz
Mainz, Germany
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.